跳至主要内容
临床试验/NCT02275312
NCT02275312已完成不适用

ETREAT: A Prospective Observational Study to Evaluate the Effectiveness of Botulinum Toxin Type A (BoNT-A) Injections in Patients With Post-stroke Upper and/or Lower Limb Spasticity in the Early Stage of Spasticity Development.

Ipsen0 个研究点目标入组 110 人开始时间: 2014年7月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Ipsen
入组人数
110
主要终点
Change in Goal Attainment Scale (GAS) score.

研究概览

简要总结

The objective of this study is to evaluate the effectiveness of BoNT-A on functional improvement in patients with post-stroke upper and/or lower limb spasticity in the early stage of spasticity development, according to routine clinical practice.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Prospective

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Men and women ≥ 18-80 years.
  • Poststroke limb spasticity.
  • Patients who have suffered a stroke in the previous 6 months.
  • Treatment goal has been previously agreed with the patient or their legal representative.
  • Patients with clinically significant poststroke upper/lower limb spasticity, in whom it has been decided to perform multidisciplinary treatment with BoNT-A + rehabilitation.
  • No previous treatment with BoNT-A.
  • Patient is able to follow the protocol.
  • Written informed consent.

排除标准

  • Neuromuscular disease.
  • Use of drugs that interfere with neuromuscular transmission.
  • Any other condition that could interfere with rehabilitation or evaluation of the results.
  • Diagnosis of spasticity not associated with stroke.
  • Pregnant or nursing mothers.
  • Prior participation in any other study in the 6 months before study entry

结局指标

主要结局

Change in Goal Attainment Scale (GAS) score.

时间窗: Baseline, 16 months

次要结局

  • Change in Modified Ashworth Scale (MAS) score.(Baseline, 16 months)
  • Change on EQ-5D quality of life questionnaire(Baseline, 16 months)
  • Time interval between injections(From baseline up to 16 months)
  • Change in pain according to Visual Analog Scale (VAS).(Baseline, 16 months)
  • Cost per patient(From baseline up to 16 months)
  • Spasticity patterns will be defined in patients with upper and/or lower limb spasticity in the early stage after stroke(Baseline, 16 months)
  • Baseline characteristics of patients(Baseline)
  • Percentage of patients reporting functional improvement evaluated by Goal Attainment Scale (GAS) score.(From baseline up to 16 months)
  • Passive function of upper and/or lower limbs according to primary treatment target (PTT) from the disability assessment scale (DAS).(Baseline, 16 months)
  • Comfortable barefoot walking speed, measured with the 10-meter walking speed test.(Baseline, 16 months)
  • Estimation of use of healthcare resources and costs associated with management of spasticity.(From baseline up to 16 months)

研究者

发起方
Ipsen
申办方类型
Industry
责任方
Sponsor

相似试验